Azitra (AZTR) Other Non-Current Assets (2022 - 2026)
Azitra (AZTR) posted Other Non-Current Assets of $47228.0 for Q1 2026, little changed on a QoQ basis from $47402.0 in Q4 2025, and up 0.61% year-over-year from $46942.0 in Q1 2025.
Azitra (AZTR) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Azitra's Other Non-Current Assets history runs 5 years deep, the most recent figure standing at $47228.0 for Q1 2026.
- Quarterly Other Non-Current Assets rose 0.61% year-over-year to $47228.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47228.0 (up 0.61% YoY) and the FY2025 annual result came in at $47402.0, up 0.98% from the prior year.
- Other Non-Current Assets was $47228.0 for Q1 2026 at Azitra, roughly flat from $47402.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.2 million in Q2 2023 and bottomed at $46941.0 in Q4 2024.
- A 5-year average of $353635.8 and a median of $47409.0 in 2025 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets sank 97.83% — and 2025, when it climbed 0.98%.
- Azitra's Other Non-Current Assets stood at $47507.0 in 2022, then advanced by 0.53% to $47760.0 in 2023, then dropped by 1.71% to $46941.0 in 2024, then advanced by 0.98% to $47402.0 in 2025, then fell by 0.37% to $47228.0 in 2026.
- Business Quant data shows AZTR's Other Non-Current Assets at $47228.0 in Q1 2026, $47402.0 in Q4 2025, and $47239.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - | - |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - | 60,000.00 |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn | 104.24 Mn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn | 1.26 Bn |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn | 2.13 Bn |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - | 289.41 Mn |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn | 124.00 Mn |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn | 63.55 Mn |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - | 14.48 Mn |
| 10 | Azitra | 2.05 Mn | 2.05 Mn | - | 47,228.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47,228.00 |
| Dec 31, 2025 | 47,402.00 |
| Sep 30, 2025 | 47,239.00 |
| Jun 30, 2025 | 47,409.00 |
| Mar 31, 2025 | 46,942.00 |
| Dec 31, 2024 | 46,941.00 |
| Sep 30, 2024 | 47,531.00 |
| Jun 30, 2024 | 47,404.00 |
| Mar 31, 2024 | 47,541.00 |
| Dec 31, 2023 | 47,760.00 |
| Sep 30, 2023 | 1.89 Mn |
| Jun 30, 2023 | 2.19 Mn |
| Dec 31, 2022 | 47,507.00 |